Publish fast. Openly. Without restrictions.

F1000Research is an **Open Research** publishing platform for scientists, scholars and clinicians offering rapid publication of articles and other research outputs without editorial bias.

HOW IT WORKS (/ABOUT)

SUBJECT AREAS | Browse all →

Natural Sciences

Medical and Health Sciences

Social Sciences

Engineering and Technology

Agricultural and Veterinary Sciences

Humanities and the Arts

RECENT ARTICLES | Browse all →

09 MARCH 2022
Molecular mechanisms of flavonoids and their modulatory effects against breast c...

09 MARCH 2022
Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota

09 MARCH 2022
A multi-spectral myelin annotation tool for machine learning based myelin quantifica...

"

To see a paper in five days, in a professional layout, is quite astounding. Two useful peer review reports appeared in less than two weeks.

Jurgen Schnermann
NIDDK/NIH
Bethesda, USA

Susan Holmes
Department of Statistics
Stanford University
California, USA

Etienne Joly
IPBS, CNRS
Université de Toulouse
Toulouse, France

Why you should publish with us

Benefits for Researchers

- ○ Enables authors, not editors, to decide what they wish to publish.
- ○ Authors suggest peer reviewers and control the process.
- ○ All types of research can be published rapidly: traditional articles, data sets, null results, protocols, case reports, incremental findings and more.

Benefits for Research

- ○ Aims to shift the way research and researchers are evaluated.
- ○ Moves away from journal-based measures towards direct assessment of individual outputs.
- ○ Supports research assessment based on the intrinsic value of the research, not the venue of publication.

Benefits for Society

- ○ Reduces the barrier to collaborative research through data sharing, transparency and attribution.
- ○ Reduces research waste and helps to remove the bias in our understanding of research.
- ○ Enables others to build upon new ideas right away, wherever and whoever they are.

Featured Updates

10 Feb 2022

Coproducing quality in healthcare: A multidimensional model

Dr. Peter Lachman

02 Feb 2022

Two truths and a lie: data in the humanities and social sciences

Lois Elliot

27 Jan 2022

How energy modelling can support policymaking for the European Green Deal

Dr. Diana Süsser

VIEW ALL UPDATES (HTTPS://BLOG.F1000.COM/BLOGS/F1000RESEARCH/)

Our Gateways

Gateways provide personalized portals for institutions or organizations, with links to other resources.

Médecins Sans Frontières

MSF publish articles, posters, slides and videos from their Scientific Days, as well as research carried out by their doctors in the field.

ELIXIR

The ELIXIR gateway publishes articles, use cases, strategy documents, technology developments, reviews, posters and slides relating to ELIXIR's activities.

Global Open Data for Agriculture and Nutrition

The GODAN gateway publishes articles on open agriculture or nutrition projects, tools and analyses, together with reports by the GODAN initiative.

International Decision Support Initiative

iDSI publishes research articles, process and methods guides, country case studies, policy briefs and more to enhance priority-setting in health.

BROWSE ALL GATEWAYS (/GATEWAYS)

Home » Advisory Board

Advisory Board

The Advisory Board of F1000Research comprises a large group of leading experts across biology and medicine. They do not act as Editors in the traditional sense (they do not handle manuscripts or make decisions to accept or reject a paper), but they provide strategic input on the direction we should take with F1000Research. They occasionally advise us on issues arising with specific articles, and many members of the board also review for us.

A B C D E F G H I J K L M N O P R S T U V W X Y Z

B
Ian Beales
Nelson Bennett
Avri Ben-Ze'ev
Benedikt Berninger
Eric Beyer
Azra Bihorac
Daniel Bikle
Kevin J Black
Chellakkan Selvanesan Blesson
Erin Aiello Bowles
Bruce Brew

C
David Catcheside
Andrew Chalmers
Tak Mao Chan
Karen Chapman
Declan Chard
Walter Chazin
Jonathan Chernoff
Cheng-Ming Chiang
Ryan Chisholm
Wei-Sheng Chong
Sandra Citi
Vitaly Citovsky
Tim Clark
James Coker
Giuseppe Colloca
William Colmers
Jason Crawford
David Criddle

D
Ira Daar
Linda Dagi
Blossom Damania
Eric Dannaoui
Vinicio de Jesus Perez
Sharon DeMorrow
Gonzalo G de Polavieja
Saskia de Wildt
Harriet de Wit
Eleftherios P Diamandis
Phedias Diamandis
Betty Diamond
J Alan Diehl
Petya Dimitrova
Annette Dolphin
Lucy Donaldson
Sylvie Doublié
Paschalis-Thoma Doulias
Crislyn D'Souza-Schorey
James Duffin
Janice Du Mont

E
Sharyn Endow
Markus Engstler
Sam Enna
Erim Erdem

F
Alastair Ferguson
Gerardo Ferrara
Richard Festenstein
Thomas Finger
Céline Fiset
Heike Fölsch
Steven Frank
Bernd Fritzsch

G
Gus Gazzard
Jozef Gécz
Robert Gerlai
Ivan Gerling
Carole Goble
Richard Gomer
Andrew Goryachev
John Greenspan
Guy Griebel
W Sue Griffin
Elizabeth Grove
Jaime Grutzendler
Wei Guo

H
Adam Hartman
Johannes Hell
Winston Hide
Stephen Hoffman
Stephen Holgate
Thorsten Hoppe
Wolfgang Huber
Arthur Hurwitz

I
Radu Iliescu
Robert Insall
Harry Ischiropoulos

J
Jan Jakobsson
Guilhem Janbon
Michael Joannidis
Norman Johnson
Etienne Joly

K
Dieter Kabelitz
Wael Kafienah
Chaya Kalcheim
Lynn Kamerlin
Mikhail Kazachkov
Johannes S Kern
Jean-Pierre Kinet
Edward Kipreos
Fenella Kirkham
Gordon Klein
Alisa Koch
Amos Korczyn
Benoit Kornmann
Jan Kucera
Anuj Kumar
Saravana Kumar

L
Eileen Lafer
Hans Lassmann
Mario Lebendiker
John Lee
Laurel Lenz
Simon Levin
Stefan Linder
Ton Lisman
Creighton M Litton
Hartmut Lode
Theresa Lu
Robyn Lucas
Ben Lugtenberg
Paul Lyons

M
Roberto Maggi
Martin Marinus
M Rashad Massoud
Jocelyn McDonald
Robert McPeek
Anthony Means
Julien Mendlewicz
Arthur Mercurio
Ralph Mistlberger
Ali Mobasheri
David Moher
Randall Moon
Carlos Morel
Dimitrios Morikis
Nicola Mulder

N
Corey Nislow

O
Chiadi Onyike

P
Leonid Padyukov
Eleftherios Paschalis
Graham Pawelec
Ming Pei
Giampaolo Perna
Stephen Pinfield
Michel Pohl
Simon Portsmouth
David Potter
Chaim Putterman

R
Adam Ratner
Ana Recober
Victor Reus
José Luis Riechmann
Karin Romisch
Vincent Rotello
Barry Rouse
Gloria Rudenko
James Russell

S
Philippe Saas
Paul R Sanberg
Alan Schechter
Werner Scheithauer
Tamar Schlick
Thomas Schnider
Alfons Schnitzler
Irene Schulz
Michael Sendtner
Andrew D Sharrocks
Nilabh Shastri
Kazim Sheikh
Andrew Shennan
Xiao Shifu
Chiara Simonelli
Helmy Siragy
Cassian Sitaru
Richard Smith
H Peter Soyer
Pamela Stanley
Christoph Stein
Carly Stevens
Charles Stevens
Bruno Stieger

An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.

BROWSE
GATEWAYS
COLLECTIONS
HOW IT WORKS

BLOG
CONTACT
FOR DEVELOPERS
RSS

Follow us

Check for updates

SYSTEMATIC REVIEW

The association between therapeutic plasma exchange and the risk of mortality among patients critically ill with COVID-19: a meta-analysis [version 1; peer review: 2 approved, 2 approved with reservations]

Shinta Oktya Wardhani [iD]1, Jonny Karunia Fajar [iD]2, Gatot Soegiarto [iD]3, Laksmi Wulandari4, Helnida Anggun Maliga [iD]5, Muhammad Ilmawan [iD]5, Risna Merysa6, Arlentina Bentivolia Simamora2, Qurrata Aini6, Komang Noviantari6, Ayu Widya Lestari7, Maria Yoheni Harnila6, Imam Syafi'i8, Jane Andrea Christiano Djianzonie9, Nenci Siagian10, Sri Nining6, Risyda Zakiyah Hanim6, Wahyuni Wahyuni11, Fitri Aulia11, Juliansyah Juliansyah6, Reflin Mahmud6, Fredo Tamara2, Aditya Indra Mahendra [iD]2, Amanda Cininta Wowor2, Fikri Baladraf2, Ponda Hernest Hadinata2, Adhityari Ikkeputri2, Hana Nadya2, Dessy Aprilia Kartini5, Milda Husnah12,13, Firzan Nainu [iD]14, Harapan Harapan [iD]12,15,16

1Division of Hematology and Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65145, Indonesia
2Brawijaya Internal Medicine Research Center, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65145, Indonesia
3Division of Allergy & Immunology, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, 60286, Indonesia
4Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, 60286, Indonesia
5Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65145, Indonesia
6Faculty of Nursing, Universitas Indonesia, Jakarta, 10430, Indonesia
7Faculty of Nursing, Universitas Syiah Kuala, Banda Aceh, Aceh, 23111, Indonesia
8Faculty of Pharmacy, Universitas Indonesia, Jakarta, 10430, Indonesia
9Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia
10Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, 60286, Indonesia
11Faculty of Public Health, Universitas Indonesia, Jakarta, 10430, Indonesia
12Medical Research Unit, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Aceh, 23111, Indonesia
13Faculty of Mathematics and Natural Sciences, Universitas Syiah Kuala, Banda Aceh, Aceh, 23111, Indonesia
14Faculty of Pharmacy, Hasanuddin University, Tamalanrea, Makassar, 90245, Indonesia
15Tropical Disease Centre, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Aceh, 23111, Indonesia
16Department of Microbiology, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Aceh, 23111, Indonesia

Open Peer Review

Approval Status ✓ ? ✓ ?

Abstract

Background: Cytokine storm has been widely known to contribute to the development of the critical condition in patients with coronavirus disease 2019 (COVID-19), and studies had been conducted to assess the potential aspect of cytokine storm elimination by performing therapeutic plasma exchange (TPE). However, contradictory findings were observed. The objective of this study was to assess the association between TPE and the reduction of mortality of critically ill COVID-19 patients.

Methods: A meta-analysis was conducted by collecting data from PubMed, Scopus, and Web of Science. Data on the mortality rate of critically ill COVID-19 patients treated with TPE plus standard of care and that of patients treated with standard of care alone were analyzed using a Z test.

Results: We included a total of four papers assessing the association between TPE and the risk of mortality among critically ill COVID-19 patients. Our findings suggested that critically ill COVID-19 patients treated with TPE had lower risk of mortality compared to those without TPE treatment.

Conclusion: Our study has identified the potential benefits of TPE in reducing the risk of mortality among critically ill COVID-19 patients.

Keywords

COVID-19; therapeutic plasma exchange; cytokine storm; treatment

	1	2	3	4
version 1 14 Dec 2021	✔ view	? view	✔ view	? view

1. **Seyi Samson Enitan** (iD), Babcock University, Ilishan-Remo, Nigeria

2. **Guilherme Welter Wendt** (iD), Universidade Estadual do Oeste do Paraná (UNIOESTE), Francisco Beltrão, Brazil

3. **Mahir Gachabayov** (iD), New York Medical College, Valhalla, USA

4. **Ashish Kumar** (iD), St Johns's Medical College Hospital, Bangalore, India

Any reports and responses or comments on the article can be found at the end of the article.

This article is included in the Emerging Diseases and Outbreaks gateway.

This article is included in the Coronavirus collection.

Corresponding authors: Shinta Oktya Wardhani (shinta_oktya.fk@ub.ac.id), Jonny Karunia Fajar (gembyok@gmail.com), Gatot Soegiarto (gatot_soegiarto@fk.unair.ac.id)

Author roles: Wardhani SO: Conceptualization, Investigation, Methodology, Supervision, Validation; **Fajar JK**: Conceptualization, Investigation, Methodology, Supervision, Validation; **Soegiarto G**: Conceptualization, Formal Analysis, Investigation, Methodology, Supervision, Validation; **Wulandari L**: Supervision, Validation; **Maliga HA**: Conceptualization, Methodology, Validation; **Ilmawan M**: Formal Analysis, Investigation, Methodology, Software, Writing – Original Draft Preparation; **Merysa R**: Data Curation, Project Administration, Resources, Visualization; **Simamora AB**: Data Curation, Investigation, Project Administration, Resources, Visualization; **Aini Q**: Data Curation, Investigation, Project Administration, Resources, Validation; **Noviantari K**: Data Curation, Investigation, Project Administration, Software, Visualization; **Lestari AW**: Data Curation, Investigation, Project Administration, Resources, Visualization; **Harnila MY**: Data Curation, Investigation, Project Administration, Resources, Visualization; **Syafi'i I**: Data Curation, Investigation, Project Administration, Resources, Visualization; **Djianzonie JAC**: Data Curation, Project Administration, Resources, Visualization; **Siagian N**: Data Curation, Project Administration, Resources, Visualization; **Nining S**: Data Curation, Project Administration, Resources, Visualization; **Hanim RZ**: Data Curation, Project Administration, Resources, Visualization; **Wahyuni W**: Data Curation, Project Administration, Resources, Visualization; **Aulia F**: Data Curation, Project Administration, Resources, Visualization; **Juliansyah J**: Data Curation, Project Administration, Resources, Visualization; **Mahmud R**: Data Curation, Project Administration, Resources, Visualization; **Tamara F**: Data Curation, Project Administration, Resources, Visualization; **Mahendra AI**: Data Curation, Project Administration, Resources, Visualization; **Wowor AC**: Data Curation, Project Administration, Resources, Visualization; **Baladraf F**: Data Curation, Project Administration, Resources, Visualization; **Hadinata PH**: Data Curation, Project Administration, Resources, Visualization; **Ikkeputri A**: Data Curation, Project Administration, Resources, Visualization; **Nadya H**: Data Curation, Project Administration, Resources, Visualization; **Kartini DA**: Data Curation, Project Administration, Resources, Visualization; **Husnah M**: Data Curation, Project Administration, Resources, Visualization; **Nainu F**: Data Curation, Project Administration, Resources, Visualization; **Harapan H**: Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Introduction

Since first reported in December 2019,[1] coronavirus disease 2019 (COVID-19) has become an unresolved global pandemic. The challenge of the pandemic management at the present time might be due to the fact that a number of mutations have occurred making the virus more transmissible and causing critical illness.[2] The World Health Organization (WHO) has established a living guideline on drugs for the management of COVID-19[3] and updated it periodically. However, the treatment of critically ill COVID-19 patients remains a serious issue.[4] Patients critically ill with COVID-19 have been widely reported to have a poor prognosis, and theory reveals that cytokine storm might underlie this mechanism. In a cytokine storm excessive accumulation of pro-inflammatory cytokines might be responsible for the poor prognosis of COVID-19 patients. No study has found an effective treatment for the management of a cytokine storm in patients critically ill with COVID-19. Therefore, an investigation into the treatment that acts to remove these pro-inflammatory cytokines, for example, using therapeutic plasma exchange (TPE) may be required.

Since first introduced in 1952, TPE has been shown to provide an excellent outcome in patients with multiple myeloma to control hyperviscosity.[5] Moreover, the implementation of this therapeutic treatment has also been reported in an *Escherichia coli* outbreak,[6] a Shigella infection,[7] infectious toxicosis,[8] and septic shock with multiple organ failure[9]; and reduced risk of mortality was revealed. In the case of COVID-19, the US Food and Drug Administration (FDA) has posited that TPE may have a role as a rescue therapy in critically ill patients with COVID-19.[10] However, insufficient evidence has resulted in indecision in applying TPE for the management of critically ill COVID-19 patients. To date, TPE has been studied in Oman,[11] Turkey,[12] Pakistan,[13] and Saudi Arabia.[14] However, contradictory findings exist. Therefore, our study aimed to assess the potential of TPE in reducing mortality of critically ill COVID-19 patients using a meta-analysis approach. The findings might add new insight and clarify the true potency of TPE for treating patients critically ill with COVID-19.

Methods

Study design

From March to August 2021, a meta-analysis following the protocols of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)[15] was conducted to evaluate the effectiveness of TPE in reducing the mortality rate of critical COVID-19 patients. The PRISMA checklist in our present study is presented as extended data in Figshare.[16] The major databases including PubMed, Scopus, and Web of Science were used to search for potential articles.

Eligibility criteria

Inclusion and exclusion criteria were defined to assess relevant articles. The inclusion criteria of the study were (1) observational or randomized controlled trial studies, (2) having adequate information to calculate the potential association and effect estimates, and (3) applying a well-defined methodological approach to establish a COVID-19 diagnosis. All case reports, case series, letters to the editor, reviews, and commentaries, as well as studies with pre-post test comparison, and poor-quality methodology assessed with the Newcastle-Ottawa scale (NOS) were excluded.

Search strategy and data extraction

The source databases used in our study were PubMed, Scopus, and Web of Science. We restricted the searching period up to 28 July 2021, and the language was English only. The Medical Subject Headings were: ("COVID-19" or "SARS-CoV-2") and ("plasma exchange" or "therapeutic plasma exchange" or "TPE"). The reference lists of all potential related articles were also assessed to retrieve additional relevant articles. Data extraction was performed for all included papers, including: (1) name of the first author; (2) year of publication; (3) country of origin; (4) sample size of cases and controls; (5) TPE, and (6) mortality rate between groups.

Assessment of the methodology quality

All included articles were assessed for their quality using NOS for observational studies[17] and the Jada-modified scale for RCTs.[18] The article quality was interpreted as low, moderate, and high. Low quality articles were excluded from our study. The assessment was performed by two independent authors (MI, HAM), and when a discrepancy was observed an assessment by a senior researcher (JKF) was conducted.

Outcome measure

The main outcome of the study was all causes of mortality among critical COVID-19 patients treated with and without TPE. The diagnosis of COVID-19 was established by using RT-PCR of SARS-CoV-2 RNA from nasal or oropharyngeal swab samples, and critical COVID-19 patients were defined by following the guideline (requires life sustaining treatment, acute respiratory distress syndrome, sepsis, or septic shock).[3,19]

Statistical analysis

The calculation of potential publication bias, heterogeneity among studies, and the association between the use of TPE and the risk of mortality among patients with COVID-19 were assessed using an Egger test, a Q test, and a Z test; respectively. The Egger test with a p-value more than 0.05 indicated the presence of potential publication bias. Moreover, the heterogeneity among studies was considered when the p-value of a Q test indicated less than 0.10. The pooled association was calculated using a Z test, where the p-value of less than 0.05 indicates a significant association. The estimated effect was presented as an odds ratio with 95% confidence interval (OR 95% CI). The cumulative calculation was presented as a forest plot. An R package software (R Studio version 4.1.1, MA, USA, (RRID:SCR_000432) was used to perform the analyses.

Results

Studies selection

We identified a total of 255 papers. Among them, four papers were excluded due to duplication and additional 227 papers due to irrelevant context. There were 24 papers in total included for full-text assessment. Then, 20 of the 24 papers were


Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart of article selection in our meta-analysis.

Table 1. Baseline characteristics of articles included in our study.

Study and year	Country	Study design	Quality	TPE		Control	
				Total	Mortality	Total	Mortality
Khamis *et al.*, 2020[11]	Oman	Cohort Retrospective	High	11	1	20	9
Gucyetmez *et al.*, 2020[12]	Turkey	Cohort Retrospective	Moderate	12	1	12	7
Kamran *et al.*, 2020[13]	Pakistan	Cohort Retrospective	High	45	4	45	18
Faqihi *et al.*, 2020[14]	Saudi Arabia	RCT	High	43	9	44	15

Source	OR (95% CI)
Khamis *et al.*, 2020	0.08 [0.00; 1.52]
Kamran *et al.*, 2020	0.16 [0.05; 0.50]
Faqihi *et al.*, 2020	0.18 [0.07; 0.45]
Gucyermez *et al.*, 2020	0.27 [0.07; 1.01]
Keith *et al.*, 2020	0.37 [0.15; 0.90]
Total	0.22 [0.13; 0.39]

Heterogeneity: $\chi^2_4 = 2.30$ ($P = .68$), $I^2 = 0\%$
Test for overall effect: $t_4 = -7.45$ ($P = .002$)

Figure 2. Forest plot of mortality rate between therapeutic plasma exchange vs control (OR: 0.2097; 95% CI: 0.0516, 0.852; p-value: 0.0382; pHet: 0.2065; pE: 02153).

further excluded since 18 were reviews and case reports and two papers had insufficient data. Four papers were included in the final analysis.[11–14] The article selection PRISMA flowchart is presented in Figure 1 and the baseline characteristics are described in Table 1.

TPE treatment and COVID-19 mortality rate

A total of 111 COVID-19 patients treated with TPE and 121 COVID-19 patients without TPE, retrieved from three retrospective cohort studies and one RCT, were included in our analysis. Our results found that COVID-19 patients treated with TPE had reduced mortality rate compared to COVID-19 patients without TPE treatment (OR: 0.21; 95% CI: 0.05, 0.85) (Figure 2).

Heterogeneity and potency of bias across the studies

Our analysis revealed the absence of the evidence of heterogeneity. Therefore, we applied a fixed-effect model to assess the correlation. For the potency of bias assessment across the studies, our analysis using an Egger test found no publication bias.

Discussion

Our study identified that TPE treatment in critically ill COVID-19 patients reduced the mortality rate. To date, our study is the first meta-analysis to report on the use of TPE for the management of COVID-19. In our analyses, we included four studies from Oman,[11] Turkey,[12] Pakistan,[13] and Saudi Arabia[14]; and all reports revealed similar findings in which TPE treatment reduced mortality among patients with COVID-19. TPE has been applied and proved to reduce the risk of mortality in the management of several infectious diseases, such as *Escherichia coli* O157:H7-associated hemolytic uremic syndrome,[6,20] Shigella infection,[7] infectious toxicosis,[8] HIV infection,[21] peripheral HIV neuropathy,[22] Kaposi's sarcoma,[21] disseminated cryptococcosis,[23] and septic shock with multiple organ failure.[9] Moreover, in the case of the *Escherichia coli* O157 outbreak in 1996, TPE proved beneficial in the reduction of mortality.[6] Therefore, as suggested in our study, TPE might possess potential benefits in COVID-19 treatment.

The precise mechanism of how TPE benefits COVID-19 patients remains debatable. In critical COVID-19 patients, the excessive accumulation of cytokines may occur, and this can lead to a fatal outcome. Previous studies have revealed that the levels of pro-inflammatory cytokines/chemokines including interleukin-2 (IL-2), interleukin-6 (IL-6), granulo-cyte colony stimulating factor (GCSF), IFN-γ inducible protein 10, monocyte chemoattractant protein 1 (MCP-1),

macrophage inflammatory protein 1A, tumor necrosis factor-α (TNF-α) were observed to be higher in patients critically ill with COVID-19 compared to those with mild-moderate disease.[24,25] TPE is a therapeutic procedure principally acting to remove (through double filtration) molecules of 60–140 nm in size.[5] The molecule size of pro-inflammatory cytokines/chemokines is 80–220 nm.[26] Therefore, the elimination of pro-inflammatory cytokines/chemokines, proven to affect those critically ill with COVID-19 might provide benefits to improve the prognosis of COVID-19 patients. Moreover, a previous study also reported that TPE played an important role in eliminating toxic substances by suppressing the cytokine release syndrome.[27] It was also suggested that TPE plays a crucial role in restoring normal substances that may be deficient in the plasma,[5] leading to stabilization and restoration of endothelial membranes.[28] Another possibility is when fresh frozen plasma was used in fluid replacement; TPE was associated with the improvement of coagulopathy in COVID-19 patients.[29] Previous evidence suggests that TPE might play an important role in maintaining the balance between anti and pro-inflammatory cytokines in the plasma, and might rectify the prognosis in patients with COVID-19, as reported in our study.

To the best of our knowledge, our study is the first meta-analysis reporting the benefit of TPE in reducing the mortality rate of critically ill COVID-19 patients. We found that COVID-19 patients treated with TPE had a lower risk of mortality compared to those without TPE treatment. Since COVID-19 guidelines suggest that the use of TPE for patients with COVID-19 should be carefully implemented as the evidence of TPE efficacy was only limited to a case report,[3] our current findings might strengthen the evidence that the use of TPE is effective in reducing the risk of mortality among patients with COVID-19. However, in real-world implementation, special settings such as appropriate condition, target of treatment, potential complications, and particular case or comorbidity should be investigated.

Since this is the initial evidence on the potential efficacy of TPE for the management of COVID-19, several limitations should be highlighted. First, we did not include any potential confounding factors such as comorbidity, the levels of proinflammatory cytokines, and onset of disease course to describe the association between TPE and the risk of mortality rate. Second, a limited number of investigations on the use of TPE in COVID-19 management resulted in our study including only a limited number of articles. Therefore, further investigation involving a larger sample size is required. Third, the clinical setting on the use of TPE might differ among studies, and therefore, this variation might also govern the potency of bias. Fourth, among the included studies, we obtained only one randomized control trial (RCT) and three observational studies. Further meta-analyses involving only RCT studies might provide better levels of evidence.

Conclusion

The data suggests that the use of TPE for the management of critically ill COVID-19 patients could reduce the mortality rate. The application of TPE for the management of COVID-19 should be considered in well-equipped hospitals.

Data availability
Underlying data

All data underlying the results are available as part of the article and no additional source data are required.

Reporting guidelines

Figshare: PRISMA checklist for 'the association between therapeutic plasma exchange and the risk of mortality among patients with critically ill COVID-19: a meta-analysis. https://doi.org/10.6084/m9.figshare.16622572.v1[16]

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

Acknowledgements

References

1. Wang C, Horby PW, Hayden FG, *et al.*: **A novel coronavirus outbreak of global health concern.** *Lancet.* 2020; **395**: 470–473.
   PubMed Abstract | **Publisher Full Text**

2. Coccia M: **The impact of first and second wave of the COVID-19 pandemic in society: comparative analysis to support control measures to cope with negative effects of future infectious diseases.** *Environ Res.* 2021; **197**: 111099.
   PubMed Abstract | **Publisher Full Text**

3. Rochwerg B, Agarwal A, Siemieniuk RA, *et al.*: **A living WHO guideline on drugs for covid-19.** *BMJ.* 2020; **370**: m3379.

4. Salluh JIF, Arabi YM, Binnie A: **COVID-19 research in critical care: the good, the bad, and the ugly.** *Intensive Care Med.* 2021; **47**:

470–472.
PubMed Abstract | **Publisher Full Text**

5. Simon TL, Snyder EL, Stowell CP, *et al*.: *Rossi's principles of transfusion medicine.* John Wiley & Sons; 2009.
Publisher Full Text

6. Dundas S, Murphy J, Soutar RL, *et al*.: **Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157: H7 outbreak.** *Lancet.* 1999; **354**: 1327–1330.
PubMed Abstract | **Publisher Full Text**

7. Brocklebank V, Wong EK, Fielding R, *et al*.: **Atypical haemolytic uraemic syndrome associated with a CD46 mutation triggered by Shigella flexneri.** *Clin Kidney J.* 2014; **7**: 286–288.
PubMed Abstract | **Publisher Full Text**

8. Burakovskii NI, Sviridchuk VM: **A case using plasmapheresis in treating infectious toxicosis in young infants.** *Pediatriia.* 1988; 98–99.
PubMed Abstract

9. Keith PD, Wells AH, Hodges J, *et al*.: **The therapeutic efficacy of adjunct therapeutic plasma exchange for septic shock with multiple organ failure: a single-center experience.** *Crit Care.* 2020; **24**: 518.
PubMed Abstract | **Publisher Full Text**

10. Tabibi S, Tabibi T, Conic RRZ, *et al*.: **Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients.** *J Intensive Care Med.* 2020; **35**: 827–835.
PubMed Abstract | **Publisher Full Text**

11. Khamis F, Al-Zakwani I, Al Hashmi S, *et al*.: **Therapeutic plasma exchange in adults with severe COVID-19 infection.** *Int J Infect Dis.* 2020; **99**: 214–218.
PubMed Abstract | **Publisher Full Text**

12. Gucyetmez B, Atalan HK, Sertdemir I, *et al*.: **Therapeutic plasma exchange in patients with COVID-19 pneumonia in intensive care unit: a retrospective study.** *Crit Care.* 2020; **24**: 492.
PubMed Abstract | **Publisher Full Text**

13. Kamran SM, Mirza ZE, Naseem A, *et al*.: **Therapeutic plasma exchange for coronavirus disease-2019 triggered cytokine release syndrome; a retrospective propensity matched control study.** *PLoS One.* 2021; **16**: e0244853.
PubMed Abstract | **Publisher Full Text**

14. Faqihi F, Alharthy A, Abdulaziz S, *et al*.: **Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial.** *Int J Antimicrob Agents.* 2021; **57**: 106334.
PubMed Abstract | **Publisher Full Text**

15. Liberati A, Altman DG, Tetzlaff J, *et al*.: **The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.** *BMJ.* 2009; **339**: b2700.
PubMed Abstract | **Publisher Full Text**

16. Fajar J, *et al*.: **The association between therapeutic plasma exchange and the risk of mortality among patients with critically ill COVID-19: a meta-analysis. Figshare.** *Dataset.* 2021.
Publisher Full Text

17. Stang A: **Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.** *Eur J Epidemiol.* 2010; **25**: 603–605.
PubMed Abstract | **Publisher Full Text**

18. Olivo SA, Macedo LG, Gadotti IC, *et al*.: **Scales to assess the quality of randomized controlled trials: a systematic review.** *Phys Ther.* 2008; **88**: 156–175.
Publisher Full Text

19. Liu J, Liu S: **The management of coronavirus disease 2019 (COVID-19).** *J Med Virol.* 2020; **92**: 1484–1490.
PubMed Abstract | **Publisher Full Text**

20. Downes KA, Allen K, Sarode R, *et al*.: **Consanguineous hemolytic uremic syndrome secondary to *Escherichia coli* O157:H7 infection treated with aggressive therapeutic plasma exchange.** *J Clin Apher.* 2001; **16**: 155–156.
PubMed Abstract | **Publisher Full Text**

21. Reiss RF, Rubinstein P, Friedman-Kien A, *et al*.: **Partial plasma exchange in patients with AIDS and Kaposi's sarcoma. Plasmapheresis in AIDS.** *AIDS Res.* 1986; **2**: 183–190.
PubMed Abstract | **Publisher Full Text**

22. Salim YS, Faber V, Skinhoj P, *et al*.: **Plasmapheresis in the treatment of peripheral HIV neuropathy.** *Ugeskr Laeger.* 1989; **151**: 1754–1756.
PubMed Abstract

23. Bollee G, Touzot M, Mechai F, *et al*.: **Plasma exchange for disseminated cryptococcosis.** *Am J Kidney Dis.* 2009; **53**: 673–676.
PubMed Abstract | **Publisher Full Text**

24. Huang C, Wang Y, Li X, *et al*.: **Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.** *Lancet.* 2020; **395**: 497–506.
PubMed Abstract | **Publisher Full Text**

25. Channappanavar R, Perlman S: **Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology.** *Semin Immunopathol.* 2017; **39**: 529–539.
PubMed Abstract | **Publisher Full Text**

26. Strauss RG, Ciavarella D, Gilcher RO, *et al*.: **An overview of current management.** *J Clin Apher.* 1993; **8**: 189–194.
Publisher Full Text

27. Padmanabhan A, Connelly-Smith L, Aqui N, *et al*.: **Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue.** *J Clin Apher.* 2019; **34**: 171–354.
PubMed Abstract | **Publisher Full Text**

28. Bar-On YM, Flamholz A, Phillips R, *et al*.: **SARS-CoV-2 (COVID-19) by the numbers.** *Elife.* 2020; **9**.
PubMed Abstract | **Publisher Full Text**

29. Zachariah U, Nair SC, Goel A, *et al*.: **Targeting raised von Willebrand factor levels and macrophage activation in severe COVID-19: Consider low volume plasma exchange and low dose steroid.** *Thromb Res.* 2020; **192**: 2.
PubMed Abstract | **Publisher Full Text**

Open Peer Review

Current Peer Review Status: ✓ ? ✓ ?

- -

Version 1

Reviewer Report 13 January 2022

https://doi.org/10.5256/f1000research.78779.r116276

? **Ashish Kumar** (iD)

Department of Critical Care Medicine, St Johns's Medical College Hospital, Bangalore, Karnataka, India

Wardhani et al., in their study titled "The association between therapeutic plasma exchange and the risk of mortality among patients critically ill with COVID-19: a meta-analysis" reported therapeutic plasma exchange to be of benefit in patients with critically ill COVID-19. I have the following comments.

Introduction
-None

Methods
- What was the statistical method used to pool data? Random/Fixed effect? What was the measure of Tau2 if IV method was used for pooling?

Results
- Summarize the quality of the included studies.
- Use GRADE criteria to grade the level of evidence.
- Baseline Table, Table 1 needs to be elaborated more with more variables to give the reader an idea about the severity of the illness among patients included.

Discussion
- The discussion needs to stress the "low quality" of included studies considering the observational nature of the study.

Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes

Are sufficient details of the methods and analysis provided to allow replication by others?
No

Is the statistical analysis and its interpretation appropriate?
Partly

Are the conclusions drawn adequately supported by the results presented in the review?
Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Nees more methodological clarification.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 10 January 2022

https://doi.org/10.5256/f1000research.78779.r116268

✔ **Mahir Gachabayov** [iD]

Section of Colorectal Surgery, Department of Surgery, Westchester Medical Center, New York Medical College, Valhalla, NY, USA

Thank you for the opportunity of reviewing this manuscript.

This is a systematic review and meta-analysis aiming at evaluating the use of therapeutic plasma exchange (TPE) in terms of mortality in critically ill COVID-19 patients as compared to a control group. The research question makes sense and is worth exploring as this topic has been speculated upon with anecdotal evidence.

The methodology of meta-analysis is adequate. The literature search was comprehensive; study screening and selection process as well as data extraction complied with PRISMA guidelines. Statistical analysis was adequate. Discussion is comprehensible and easy to read.

Conclusion drawn was partly justified by the findings of the analysis. I would evaluate certainty of evidence generated in this meta-analysis on a GRADE scale. If certainty of evidence is assessed to be low (given the limitations), I would conclude that although TPE could reduce mortality as the findings of this study suggest, current evidence is inconclusive.

Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes

Are sufficient details of the methods and analysis provided to allow replication by others?

Yes

Is the statistical analysis and its interpretation appropriate?
Partly

Are the conclusions drawn adequately supported by the results presented in the review?
Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: clinical outcomes and evidence synthesis

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 06 January 2022

https://doi.org/10.5256/f1000research.78779.r116284

?

Guilherme Welter Wendt
Psychologist and Adjunct Professor of Quantitative Research Methods, Centro de Ciências da Saúde (CCS), Universidade Estadual do Oeste do Paraná (UNIOESTE), Francisco Beltrão, Brazil

- References are needed to support these statements: "Patients critically ill with COVID-19 have been widely reported to have a poor prognosis, and theory reveals that cytokine storm might underlie this mechanism. In a cytokine storm excessive accumulation of pro-inflammatory cytokines might be responsible for the poor prognosis of COVID-19 patients".

- "No study has found an effective treatment for the management of a cytokine storm in patients critically ill with COVID-19" - how can you prove that? Perhaps it could be informative to tone down this sentence, including "to the best of our knowledge" or provide dates and keywords used in scientific databases that resulted in zero studies.

- These sentences could be merged, resulting in an objective, clear paragraph: "However, insufficient evidence has resulted in indecision in applying TPE for the management of critically ill COVID-19 patients. To date, TPE has been studied in Oman,11 Turkey,12 Pakistan,13 and Saudi Arabia.14 However, contradictory findings exist".

- Under the search strategy and data extraction, please state which authors performed these tasks (as reported for the assessment methodological quality). What happened when disagreements occurred?

- The Jada-modified scale does not appear under the section "Eligibility criteria". Should you

include, like you did with the NOS?

- In the results, you mention that studies with insufficient data were excluded. Should this appear in your inclusion/exclusion criteria too?

- The following sentence seems incomplete: "Our analysis revealed the absence of the evidence of heterogeneity. Therefore, we applied a fixed-effect model to assess the correlation". Correlation between what?

- The first paragraph of the discussion looks a little bit repetitive. The third paragraph also seems to repeat some of the information given at the beginning of the discussion.

- "Previous evidence suggests that TPE might play an important role in maintaining the balance between anti and pro-inflammatory cytokines in the plasma, and might rectify the prognosis in patients with COVID-19, as reported in our study". Can you show us (cite) the evidence mentioned?

- "our current findings might strengthen the evidence that the use of TPE is effective in reducing the risk of mortality among patients with COVID-19". Here you are not talking about severe Covid. Does it mean that TPE might benefit mild/moderate cases too?

Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes

Are sufficient details of the methods and analysis provided to allow replication by others?
Yes

Is the statistical analysis and its interpretation appropriate?
Yes

Are the conclusions drawn adequately supported by the results presented in the review?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Public health, epidemiology, statistics

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 23 December 2021

https://doi.org/10.5256/f1000research.78779.r116258

✔ **Seyi Samson Enitan** iD

Department of Medical Laboratory Science, Babcock University, Ilishan-Remo, Nigeria

This paper contributes considerably to knowledge in the field of COVID-19 management. The introduction is considered satisfactory. The authors provided background that puts the manuscript into context and allows readers outside the field to understand the purpose and significance of the study. They also identified the existing gap in knowledge that needs to be filled. The rationale for, and objectives of, the systematic review were clearly stated.

In this manuscript, the authors assessed the association between therapeutic plasma exchange (TPE) and the reduction of mortality of critically ill COVID-19 patients. A meta-analysis was conducted by collecting data from PubMed, Scopus, and Web of Science, in which a total of four papers were assessed. The methodology section was clearly presented to allow the reproduction of the study. Sufficient details of the analysis were also provided to allow replication by others. The statistical analysis and its interpretation were appropriate.

The outcome of the study shows that critically ill COVID-19 patients treated with TPE had a lower risk of mortality compared to those without TPE treatment (OR: 0.21; 95% CI: 0.05, 0.85). Hence, the need for TPE advocacy with recourse to the clinical presentation of the patient.

The study, however, is not without its attending limitations, mainly:
1. Potential confounding factors such as comorbidity, the levels of pro-inflammatory cytokines, and the onset of disease course to describe the association between TPE and the risk of mortality rate were not included.

2. The sample size was small due to the limited number of papers assessed.

3. Bias due to variation in clinical setting in the use of TPE

4. Only one randomized control trial was included in the study.

The conclusion drawn was adequately supported by the data assessed in the meta-analysis.

In all, the work is okay and the findings are worth sharing with the scientific community, however, it is important to note that the use of TPE must be done with utmost caution to forestall unexpected complications that may be associated with it.

NB: Authors should declare whether competing interests exist or not.

Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes

Are sufficient details of the methods and analysis provided to allow replication by others?
Yes

Is the statistical analysis and its interpretation appropriate?
Yes

Are the conclusions drawn adequately supported by the results presented in the review?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Immunology of infectious diseases including COVID-19, HIV/AIDS and Opportunistic infections

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias

- You can publish traditional articles, null/negative results, case reports, data notes and more

- The peer review process is transparent and collaborative

- Your article is indexed in PubMed after passing peer review

- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research

SJR   Scimago Journal & Country Rank

Enter Journal Title, ISSN or Publisher Name

Home   Journal Rankings   Country Rankings   Viz Tools   Help   About Us

F1000Research 🔓

COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	H-INDEX
United Kingdom 🏛 Universities and research institutions in United Kingdom	Biochemistry, Genetics and Molecular Biology └ Biochemistry, Genetics and Molecular Biology (miscellaneous) Immunology and Microbiology └ Immunology and Microbiology (miscellaneous) Medicine └ Medicine (miscellaneous) Pharmacology, Toxicology and Pharmaceutics └ Pharmacology, Toxicology and Pharmaceutics (miscellaneous)		**60**

PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION
Journals	20461402	2012-2020	Homepage How to publish in this journal research@f1000.com

SCOPE

F1000Research publishes articles and other research outputs reporting basic scientific, scholarly, translational and clinical research across the physical and life sciences, engineering, medicine, social sciences and humanities. F1000Research is a scholarly publication platform set up for the scientific, scholarly and medical research community; each article has at least one author who is a qualified researcher, scholar or clinician actively working in their speciality and who has made a key contribution to the article. Articles must be original (not duplications). All research is suitable irrespective of the perceived level of interest or novelty; we welcome confirmatory and negative results, as well as null studies. F1000Research publishes different type of research, including clinical trials, systematic reviews, software tools, method articles, and many others. Reviews and Opinion articles providing a balanced and comprehensive overview of the latest discoveries in a particular field, or presenting a personal perspective on recent developments, are also welcome. See the full list of article types we accept for more information.

💬 Join the conversation about this journal

Quartiles

Advances in Experimental Medicine and Biology USA	EBioMedicine NLD	Science Translational Medicine USA	Frontiers of Medicine CHN	Journal of Biomedical Science GBR
79% similarity	**78%** similarity	**73%** similarity	**73%** similarity	**71%** similarity

SJR

Total Documents

Citations per document

Total Cites **Self-Cites**

External Cites per Doc **Cites per Doc**

- Cites / Doc. (4 years)
- Cites / Doc. (3 years)
- Cites / Doc. (2 years)

% International Collaboration

Citable documents **Non-citable documents**

Cited documents **Uncited documents**

← Show this widget in your own website

Just copy the code below and paste within your html code:

`<a href="https://www.scimago`

F1000Research

Q1 Medicine (miscellaneous)

best quartile

SJR 2020

1.1

powered by scimagojr.com

Metrics based on Scopus® data as of April 2021

H **hany akeel naji**   8 months ago

I have been waiting about one year for my article to publish or review but till now nothing happened

↩ reply

Melanie Ortiz   8 months ago   SCImago Team

Dear Hany,
Thank you for contacting us.
Unfortunately, we cannot help you with your request, we suggest you contact the journal's editorial staff , so they could inform you more deeply.
Best Regards, SCImago Team

A **alemu**   12 months ago

Background: Nowadays, people die due to metabolic aging than chronological age worldwide.

Source details

F1000Research

Open Access ⓘ

Scopus coverage years: from 2012 to Present

Publisher: Taylor & Francis

   E-ISSN: 2046-1402

Subject area: (Pharmacology, Toxicology and Pharmaceutics: General Pharmacology, Toxicology and Pharmaceutics)

(Biochemistry, Genetics and Molecular Biology: General Biochemistry, Genetics and Molecular Biology)   View all ⌄

Source type: Journal

CiteScore 2020
4.4   ⓘ

SJR 2020
1.099   ⓘ

SNIP 2020
0.921   ⓘ

[View all documents >]   [Set document alert]   💾 Save to source list   Source Homepage

CiteScore   CiteScore rank & trend   Scopus content coverage

ⓘ   Improved CiteScore methodology   ✕

CiteScore 2020 counts the citations received in 2017-2020 to articles, reviews, conference papers, book chapters and data

papers published in 2017-2020, and divides this by the number of publications published in 2017-2020. Learn more >

CiteScore   2020   ⌄

$$4.4 = \frac{13.426 \text{ Citations 2017 - 2020}}{3.027 \text{ Documents 2017 - 2020}}$$

Calculated on 05 May, 2021

CiteScoreTracker 2021 ⓘ

$$4.9 = \frac{14.958 \text{ Citations to date}}{3.026 \text{ Documents to date}}$$

Last updated on 06 March, 2022 • Updated monthly

CiteScore rank 2020 ⓘ

Category	Rank	Percentile
Pharmacology, Toxicology and Pharmaceutics	#13/67	81st
└ General Pharmacology, Toxicology and Pharmaceutics		
Biochemistry, Genetics and	#60/204	70th

View CiteScore methodology >   CiteScore FAQ >   Add CiteScore to your site 🔗